These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 12402149)

  • 1. Infiltrating ductal and lobular breast carcinomas are characterised by different interrelationships among markers related to angiogenesis and hormone dependence.
    Coradini D; Pellizzaro C; Veneroni S; Ventura L; Daidone MG
    Br J Cancer; 2002 Nov; 87(10):1105-11. PubMed ID: 12402149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of cell cycle markers in well-differentiated lobular and ductal carcinomas.
    Soslow RA; Carlson DL; Horenstein MG; Osborne MP
    Breast Cancer Res Treat; 2000 May; 61(2):161-70. PubMed ID: 10942102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pleomorphic lobular carcinoma of the breast: its cell kinetics, expression of oncogenes and tumour suppressor genes compared with invasive ductal carcinomas and classical infiltrating lobular carcinomas.
    Frolik D; Caduff R; Varga Z
    Histopathology; 2001 Nov; 39(5):503-13. PubMed ID: 11737309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast.
    Brown LF; Guidi AJ; Schnitt SJ; Van De Water L; Iruela-Arispe ML; Yeo TK; Tognazzi K; Dvorak HF
    Clin Cancer Res; 1999 May; 5(5):1041-56. PubMed ID: 10353737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Invasive lobular and invasive ductal carcinoma of the breast show distinct patterns of vascular endothelial growth factor expression and angiogenesis.
    Lee AH; Dublin EA; Bobrow LG; Poulsom R
    J Pathol; 1998 Aug; 185(4):394-401. PubMed ID: 9828838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical analysis of pleomorphic lobular carcinoma: higher expression of p53 and chromogranin and lower expression of ER and PgR.
    Radhi JM
    Histopathology; 2000 Feb; 36(2):156-60. PubMed ID: 10672061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microvessel density and vascular endothelial growth factor expression in infiltrating lobular mammary carcinoma.
    Chhieng DC; Tabbara SO; Marley EF; Talley LI; Frost AR
    Breast J; 2003; 9(3):200-7. PubMed ID: 12752628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypoxia-inducible factor-1alpha is associated with angiogenesis, and expression of bFGF, PDGF-BB, and EGFR in invasive breast cancer.
    Bos R; van Diest PJ; de Jong JS; van der Groep P; van der Valk P; van der Wall E
    Histopathology; 2005 Jan; 46(1):31-6. PubMed ID: 15656883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome.
    Arpino G; Bardou VJ; Clark GM; Elledge RM
    Breast Cancer Res; 2004; 6(3):R149-56. PubMed ID: 15084238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prevalence of BCL-2 immunoreactivity in breast carcinomas and its clinicopathological correlates, with particular reference to oestrogen receptor status.
    Doglioni C; Dei Tos AP; Laurino L; Chiarelli C; Barbareschi M; Viale G
    Virchows Arch; 1994; 424(1):47-51. PubMed ID: 7981903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MR imaging features of invasive breast cancer correlated with hormonal receptors: does progesterone receptor matter?
    Chen JH; Nalcioglu O; Su MY
    Ann Oncol; 2008 May; 19(5):1024-6. PubMed ID: 18375524
    [No Abstract]   [Full Text] [Related]  

  • 12. Mitochondrial UCP4 and bcl-2 expression in imprints of breast carcinomas: relationship with DNA ploidy and classical prognostic factors.
    Gonidi M; Athanassiadou AM; Patsouris E; Tsipis A; Dimopoulos S; Kyriakidou V; Chelidonis G; Athanassiadou P
    Pathol Res Pract; 2011 Jun; 207(6):377-82. PubMed ID: 21621926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis.
    Bos R; Zhong H; Hanrahan CF; Mommers EC; Semenza GL; Pinedo HM; Abeloff MD; Simons JW; van Diest PJ; van der Wall E
    J Natl Cancer Inst; 2001 Feb; 93(4):309-14. PubMed ID: 11181778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Receptor (ER, PgR) levels as prognostic factors in the endocrine therapy of pre- and post-menopausal patients with stage III infiltrative ductal and lobular cancer of the breast].
    Calzada L; Salazar EL; Pedron Nuevo N
    Ginecol Obstet Mex; 1996 Mar; 64():135-9. PubMed ID: 8729191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Should histologic type be taken into account when considering neoadjuvant chemotherapy in breast carcinoma?
    Sullivan PS; Apple SK
    Breast J; 2009; 15(2):146-54. PubMed ID: 19292800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The ductal phenotypic expression of the E-cadherin/catenin complex in tubulolobular carcinoma of the breast: an immunohistochemical and clinicopathologic study.
    Esposito NN; Chivukula M; Dabbs DJ
    Mod Pathol; 2007 Jan; 20(1):130-8. PubMed ID: 17143261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypoxia-inducible factor-2 alpha (HIF-2 alpha) induces angiogenesis in breast carcinomas.
    Giatromanolaki A; Sivridis E; Fiska A; Koukourakis MI
    Appl Immunohistochem Mol Morphol; 2006 Mar; 14(1):78-82. PubMed ID: 16540735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cytosolic pS2 levels and cellular proliferation in ER-positive and PgR-positive infiltrating ductal carcinomas of the breast].
    Sánchez Salmón A; Argibay S; Arias JI; Ruibal A
    Rev Esp Med Nucl; 2005; 24(3):185-90. PubMed ID: 15847785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of steroid hormone receptors with respect to tumor cellularity.
    Geppert M; Smyczek-Gargya B; Dietl J; Schneider H
    Zentralbl Pathol; 1993 Aug; 139(3):217-9. PubMed ID: 8218122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thrombospondin-1 and -2 in node-negative breast cancer: correlation with angiogenic factors, p53, cathepsin D, hormone receptors and prognosis.
    Gasparini G; Toi M; Biganzoli E; Dittadi R; Fanelli M; Morabito A; Boracchi P; Gion M
    Oncology; 2001; 60(1):72-80. PubMed ID: 11150912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.